Cardiorenal syndrome

Article written and reviewed by Dr Luca Moretti

Cardiorenal syndrome encompasses conditions in which acute or chronic dysfunction of the heart or kidney induces or aggravates dysfunction of the other organ. It is not a single etiological diagnosis: it includes hemodynamic, neurohormonal, inflammatory, metabolic, and iatrogenic phenotypes requiring different assessments; the traditional classification distinguishes five types according to the initial organ and timing. It is useful for describing the context, but a patient may move between categories or have a common systemic disease; therapy must therefore be based on the dominant mechanism, not only the type number. In heart failure, venous congestion, intra-abdominal pressure, reduced perfusion pressure, and neurohormonal activation are often more important than cardiac output alone; a modest, transient rise in creatinine during effective decongestion does not necessarily equate to tubular injury.

The kidney regulates volume, electrolytes, blood pressure, and acid-base balance and modifies tolerance of cardiac drugs. The heart provides pressure and flow, while the right atrium, renal veins, and interstitium determine downstream pressure: glomerular function arises from the gradient between these compartments. Albuminuria, urinary sediment, rate of decline, and imaging distinguish intrinsic CKD from functional impairment. Attributing every deterioration to heart failure may delay diagnosis of glomerulonephritis, obstruction, toxicity, or renovascular disease; management integrates cardiology and nephrology, with goals of euvolemia, organ protection, and improved prognosis. The relative importance of creatinine, blood pressure, and congestion changes between an acute episode, chronic therapy, and advanced heart failure.

Etiology, pathogenesis, and pathophysiology

In type 1, an acute cardiac event causes AKI: heart failure, infarction, shock, arrhythmia, surgery, or embolism may reduce perfusion or increase venous pressure. Injury ranges from a reversible hemodynamic change to tubular necrosis, cholesterol emboli, or pigment nephropathy. In type 2, chronic heart failure produces progressive renal deterioration through congestion, RAAS, the sympathetic nervous system, inflammation, and repeated acute episodes; renal reserve decreases, and modest changes in blood pressure or volume cause large fluctuations in filtration. Right heart failure, tricuspid regurgitation, and pulmonary hypertension expose the kidney to persistent back pressure; elevated central venous pressure correlates with worsening more than cardiac output in many congested phenotypes.

In type 3, AKI induces cardiac dysfunction through overload, hyperkalemia, acidosis, uremia, and inflammation. Arrhythmias, pulmonary edema, and myocardial depression may occur even without previous heart disease. In type 4, CKD promotes hypertrophy, fibrosis, coronary artery disease, vascular and valvular calcification, anemia, and endothelial dysfunction; uremic cardiomyopathy integrates afterload, toxins, mineral disturbances, and energetic abnormalities. Intermittent dialysis produces changes in volume, blood pressure, and electrolytes that may cause stunning, hypotension, and arrhythmias. High-flow arteriovenous accesses may cause high-output heart failure.

In type 5, a systemic disease affects the heart and kidneys simultaneously. Sepsis, amyloidosis, diabetes, lupus, vasculitides, cirrhosis, and toxic agents are examples in which the causal direction is not unambiguous; the classification does not adequately represent shared factors such as age, obesity, and hypertension or the continuity between acute and chronic disease. Etiological phenotyping must specify the cause, congestion, perfusion, and presence of parenchymal injury. Diabetes and atherosclerosis produce albuminuria and vascular disease affecting both organs. Prevention and treatment of common factors are part of cardiorenal therapy.

Activation of RAAS, the sympathetic nervous system, and vasopressin retains sodium and water and maintains filtration through efferent arteriolar constriction. Over time, it increases afterload, fibrosis, oxidative stress, and diuretic resistance; antagonizing these systems may cause an initial hemodynamic eGFR dip but improve outcomes. Renal perfusion pressure depends on arterial pressure minus venous and interstitial pressures. Abdominal and renal congestion reduces the gradient even with apparently sufficient mean pressure; autoregulation is impaired by CKD, sepsis, and drugs. NSAIDs, contrast, calcineurin inhibitors, and nephrotoxic combinations may turn adaptation into injury.

Diuretic resistance results from reduced intestinal absorption, insufficient tubular secretion, distal hypertrophy, low perfusion, and sodium intake; increased post-diuretic reabsorption and the braking phenomenon reduce natriuresis at the same dose. Inflammation and endothelial injury increase permeability and fibrosis. Tubular biomarkers may remain low during a creatinine rise from decongestion, supporting the distinction between functional change and structural injury; hyponatremia reflects free water and severe neurohormonal activation; hyperkalemia results from CKD, acidosis, and drugs. Both signal risk and limit therapies if not actively managed.

Clinical manifestations

Dyspnea, orthopnea, edema, weight gain, elevated jugular venous pressure, ascites, and reduced exercise tolerance indicate congestion; its distribution may be pulmonary, systemic, or predominantly intravascular; obesity and low albumin make examination less sensitive. Oliguria, fatigue, nausea, pruritus, cramps, and altered mental status appear with reduced kidney function or uremia; preserved urine output does not exclude AKI, and stable creatinine does not exclude substantial congestion. Hypotension, cold extremities, and a narrow pulse pressure suggest low cardiac output, while hypertension and pulmonary edema indicate afterload mismatch. Many patients are congested with relatively preserved perfusion.

In type 1, creatinine may rise after diuresis, contrast, infection, or hypotension; timing relative to weight, natriuresis, blood pressure, and drugs helps distinguish hemoconcentration from persistent injury. Residual congestion at discharge is associated with acute decompensations and mortality; a modest creatinine bump during effective volume loss may be acceptable if perfusion, electrolytes, and symptoms remain stable. A progressive rise with oliguria, active urinary sediment, hyperkalemia, or acidosis instead requires urgent reassessment. Automatically stopping decongestion may worsen venous pressure and kidney function.

In type 2, reduced eGFR, albuminuria, anemia, and recurrent overload predominate; the patient may tolerate abnormal values for a long time but loses the ability to adapt to infections, NSAIDs, dietary changes, and medication interruption. Cardiorenal frailty manifests as frequent hospitalizations, hypotension, hyperkalemia, and an apparent inability to maintain RAAS inhibition or effective diuretic doses. Cramps, dizziness, and thirst may indicate excessive removal, but do not prove euvolemia. Orthostatic symptoms and congestion may coexist because of abnormal volume distribution.

Severe AKI may cause pulmonary edema, uremic pericarditis, arrhythmias, weakness, and confusion. Hyperkalemia produces peaked T waves, QRS widening, and cardiac arrest, but ECG may have low sensitivity. Anemia and mineral disturbances in CKD aggravate ischemia and remodeling; vascular calcification increases arterial stiffness and afterload and contributes to HFpEF prevalence. High-flow fistulas cause a bounding pulse, tachycardia, dilation, and elevated pulmonary pressures; the relationship with access and cardiac output must be measured before revision.

Atypical signs point toward primary kidney disease: glomerular hematuria, casts, marked proteinuria, rapid eGFR loss, large or small kidneys, rash, and systemic symptoms. Obstruction may present with anuria, pain, or hydronephrosis but may be silent. Fever, eosinophilia, and a new drug suggest interstitial nephritis; thrombocytopenia and hemolysis suggest microangiopathy; the concurrent diagnosis is crucial because diuretics and cardiac optimization do not treat these causes. Medication review includes NSAIDs, contrast agents, antibiotics, supplements, lithium, and cancer drugs. Nonprescription products must also be explicitly asked about.

Investigations and diagnosis

Creatinine and eGFR are interpreted relative to baseline, muscle mass, and trajectory. Cystatin C is less muscle-dependent but influenced by inflammation, thyroid function, and corticosteroids; combined equations improve estimation in selected cases. Albuminuria in a spot sample classifies risk together with eGFR. Urinalysis and urinary sediment distinguish proteinuria, hematuria, casts, and infection and must not be omitted by attributing creatinine to the heart. Electrolytes, bicarbonate, urea, complete blood count, iron status, calcium, phosphorus, PTH, and albumin define CKD complications. Short-term trends are needed during diuresis and medication changes.

Congestion assessment integrates weight, jugular veins, edema, orthopnea, radiography, lung ultrasound, and the vena cava; no single finding is accurate in every patient; the combination and response are more reliable. Echocardiography assesses chambers, valves, the right ventricle, pressures, and the pericardium; hepatic, portal, and intrarenal venous Doppler may document severe congestion, but rhythm, ventilation, and technique influence patterns. Natriuretic peptides remain useful, although they increase with CKD. Very low values make heart failure less likely; changes and context matter more than an unadjusted cutoff.

Renal ultrasound assesses size, echogenicity, cysts, and obstruction. Arterial Doppler is selected when renovascular stenosis would change treatment; incidental findings do not prove causality; biopsy is indicated for suspected glomerular, interstitial, or infiltrative disease when the result changes treatment. Procedural risk increases with anticoagulation, congestion, and small kidneys and requires shared decision-making. Amyloidosis, lupus, vasculitis, and gammopathies require targeted tests. Indiscriminate screening produces false positives and does not replace the clinical phenotype.

AKI is classified using the rise in creatinine and urine output according to KDIGO criteria, bearing in mind that fluid balance dilutes or concentrates creatinine. FENa and FEurea have limitations with diuretics, CKD, sepsis, and contrast and do not reliably distinguish prerenal from tubular disease in every case. Tubular biomarkers can contribute to research and complex scenarios, but do not replace urine sediment and clinical assessment; a rise in creatinine without injury markers during decongestion may reflect hemodynamics. Contrast exposure is weighed against the benefit of the procedure. Standard hydration may be dangerous in congested patients and must be individualized.

Right heart catheterization is reserved for uncertain hemodynamics, shock, refractory diuretic resistance, or advanced evaluation. It measures pressures and cardiac output and can distinguish true congestion from low filling when clinical and ultrasound findings disagree; the working diagnosis must include the cardiorenal type, precipitating cause, AKI or CKD stage, albuminuria, volume status, perfusion, and electrolytes. This description is more useful than nonspecific worsening of renal function; the response to a decongestive strategy is informative but does not replace exclusion of obstruction and intrinsic disease. Failure to respond requires checking dose, absorption, sodium, and diagnosis.

Treatment and prognosis

In acute congested heart failure, intravenous loop diuretics are first-line treatment, at a dose appropriate to previous exposure and renal function. Early urine output and natriuresis allow the dose to be doubled or sequential blockade to be added if the response is inadequate. Thiazides or metolazone, acetazolamide, and other approaches increase natriuresis with a risk of hyponatremia and hypokalemia; acetazolamide reduces bicarbonate and may counteract metabolic alkalosis; close monitoring of weight, urine, sodium, and creatinine guides efficacy and safety. DOSE showed no superiority of continuous administration over boluses, whereas ADVOR improved decongestion with acetazolamide in selected patients; the strategy is adapted, not copied mechanically.

Ultrafiltration removes sodium and water but is not superior as a routine approach. In CARRESS-HF, a fixed strategy worsened creatinine and events compared with stepped pharmacological therapy; it remains an option for truly refractory fluid overload or indications for dialysis. Renal replacement therapy is indicated for hyperkalemia, acidosis, uremia, poisoning, or uncontrollable volume overload, not for an isolated creatinine threshold. Continuous or intermittent treatment depends on hemodynamic stability and resources; the rate of removal must preserve perfusion and access. A rapid negative fluid balance is not a success if it causes hypotension and ischemia.

ACE inhibitors, ARBs or ARNIs, and mineralocorticoid receptor antagonists improve outcomes in HFrEF, but may increase creatinine and potassium. A limited reduction in eGFR is often hemodynamic; hypovolemia, NSAID use, bilateral renal artery stenosis, and hyperkalemia are investigated before discontinuing a therapy that improves prognosis. Beta-blockers are continued if perfusion and stability allow. SGLT2 inhibitors reduce hospitalizations and renal progression in heart failure and CKD, with a small initial eGFR dip and benefits independent of diabetes in many populations. During ketoacidosis, prolonged fasting, severe illness, or surgery, SGLT2 inhibitors are temporarily withheld. Finerenone reduces cardiorenal events in albuminuric diabetic CKD with potassium monitoring.

Hyperkalemia is treated according to severity with membrane stabilization, intracellular shifting, and removal. Modern potassium binders may support continuation of RAAS inhibitors, but do not replace urgent treatment when ECG abnormalities are present. Blood pressure and blood glucose are controlled according to guidelines, avoiding symptomatic hypotension; sodium restriction is personalized according to congestion, nutrition, and adherence; extreme fluid restrictions are rarely sustainable. NSAIDs are avoided and doses adjusted for renal function are updated. Contrast, antibiotics, and metformin are managed according to actual risk and function, avoiding both toxicity and withholding lifesaving procedures.

Anemia is investigated by assessing iron, losses, and inflammation. Intravenous iron improves symptoms and reduces some events in heart failure with iron deficiency, whereas erythropoiesis-stimulating agents are not a treatment for heart failure and require cautious targets in CKD. In advanced disease, right heart catheterization, selected inotropes, LVADs, or transplantation require an estimate of renal reversibility. Congestion and low cardiac output may improve, whereas albuminuria, imaging, and duration suggest irreversible parenchymal disease; prognosis worsens with low eGFR, albuminuria, recurrent AKI, hyperkalemia, and persistent congestion. Shared plans include dialysis, single-organ or combined transplantation, and conservative care when appropriate.

Complications

Hyperkalemia may cause lethal arrhythmias and limit effective therapies. Diuretic-induced hypokalemia and hypomagnesemia increase ectopy and digitalis toxicity; the aim is to avoid both extremes. Dilutional hyponatremia reflects severity and may cause neurological symptoms if profound or rapidly developing; overly rapid correction exposes patients to osmotic demyelination, especially in malnutrition and liver disease. Diuretic-induced alkalosis reduces ventilation and calcium ionization; CKD-related acidosis increases catabolism and dyspnea; correction addresses the cause and volume status, not only bicarbonate.

Repeated discontinuation of medications that improve prognosis may accelerate heart failure and mortality. Conversely, continuing them during shock, severe hyperkalemia, or progressive AKI may be harmful: the decision is dynamic and documented; diuretic resistance leads to increasing doses, hospitalizations, and chronic congestion. Assessment of adherence, absorption, sodium, perfusion, and the distal nephron precedes labeling the condition refractory. Intradialytic hypotension causes cardiac stunning and loss of access. Dry weight, dialysate temperature, and ultrafiltration rate are reassessed with the team.

CKD increases bleeding and thrombosis, alters pharmacokinetics, and complicates anticoagulation. Contrast agents, procedures, and devices require a balance between renal risk and cardiovascular benefit. Calciphylaxis, mineral disorders, and valvular calcification aggravate pain, infection, and stenosis. Phosphate, PTH, and vitamin D management follows nephrology recommendations, rather than empirical supplementation. Infections are more frequent with catheters, dialysis, and hospitalizations. Sepsis produces type 5 disease with rapid deterioration of both organs.

Malnutrition and sarcopenia lower creatinine and may lead to overestimation of filtration. Multiple restrictions worsen intake and frailty; a dietitian and rehabilitation balance sodium, potassium, protein, and energy; frailty alters tolerance of dialysis, LVADs, and transplantation. Assessing it does not mean denying treatment, but choosing intensity, support, and realistic goals. Depression, treatment burden, and financial difficulties reduce adherence. Simplification, education, and early follow-up are clinical interventions.

The syndrome may progress to dialysis dependence, advanced heart failure, and multiorgan failure. Recovery of creatinine does not guarantee recovery of reserve, so AKI requires subsequent monitoring of eGFR and albuminuria. Recurrent hospitalizations and treatment intolerance call for advance planning for access, transplantation, cardiac support, or conservative care. Decisions made during an emergency are often less consistent with the patient's values; follow-up with weight, blood pressure, symptoms, potassium, and function reduces delays. Success is not normalizing every number, but maintaining euvolemia, perfusion, and therapy that prolongs life.